MCID: OPD001
MIFTS: 44

Opioid Abuse

Categories: Mental diseases

Aliases & Classifications for Opioid Abuse

MalaCards integrated aliases for Opioid Abuse:

Name: Opioid Abuse 12 55 15 73
Opioid-Related Disorders 44

Classifications:



External Ids:

Disease Ontology 12 DOID:11206
ICD10 33 F11.1
ICD9CM 35 305.5
MeSH 44 D009293
SNOMED-CT 68 5602001
UMLS 73 C0029095

Summaries for Opioid Abuse

Disease Ontology : 12 A substance abuse that involves the recurring use of opioid drugs despite negative consequences.

MalaCards based summary : Opioid Abuse, also known as opioid-related disorders, is related to opiate dependence and withdrawal disorder. An important gene associated with Opioid Abuse is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Circadian entrainment and Peptide ligand-binding receptors. The drugs Morphine and Bupivacaine have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and heart, and related phenotypes are behavior/neurological and nervous system

Related Diseases for Opioid Abuse

Graphical network of the top 20 diseases related to Opioid Abuse:



Diseases related to Opioid Abuse

Symptoms & Phenotypes for Opioid Abuse

MGI Mouse Phenotypes related to Opioid Abuse:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.81 CCK CCKAR DRD2 GRIN3B MAPK10 OPRL1
2 nervous system MP:0003631 9.5 CCK CCKAR DRD2 MAPK10 OPRL1 OPRM1
3 no phenotypic analysis MP:0003012 9.02 CCK DRD2 MAPK10 OPRM1 PDYN

Drugs & Therapeutics for Opioid Abuse

Drugs for Opioid Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 119)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Morphine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 57-27-2 5288826
2
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
3
Acetaminophen Approved Phase 4,Phase 2,Not Applicable 103-90-2 1983
4
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
5
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 16590-41-3 5360515
6 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Narcotics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Ketorolac Tromethamine Phase 4
12 Cyclooxygenase Inhibitors Phase 4,Phase 2
13 Anesthetics, Local Phase 4,Phase 2,Phase 3
14 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Not Applicable
15 Antirheumatic Agents Phase 4,Phase 2,Not Applicable
16 Analgesics, Non-Narcotic Phase 4,Phase 2,Not Applicable
17 Anti-Inflammatory Agents Phase 4,Phase 2,Not Applicable
18 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
19 Antipyretics Phase 4,Phase 2
20 Narcotic Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
21
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 93-14-1 3516
22
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
23
Methadone Approved Phase 3,Phase 1,Phase 2,Not Applicable 76-99-3 4095
24
Naloxone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Not Applicable 465-65-6 5284596
25
Cocaine Approved, Illicit Phase 2, Phase 3 50-36-2 5760 446220
26
Dopamine Approved Phase 2, Phase 3,Phase 1 51-61-6, 62-31-7 681
27
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 52485-79-7 40400 644073
28
Heroin Illicit, Investigational Phase 3,Not Applicable 561-27-3 5462328
29 Chlorpheniramine, phenylpropanolamine drug combination Phase 3,Phase 1,Phase 2,Not Applicable
30 Excitatory Amino Acids Phase 3
31 Excitatory Amino Acid Antagonists Phase 3
32 Respiratory System Agents Phase 3,Phase 2,Phase 1,Not Applicable
33 Antitussive Agents Phase 3,Phase 1,Phase 2,Not Applicable
34 Neurotransmitter Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Neurotransmitter Uptake Inhibitors Phase 2, Phase 3,Phase 1
36 Vasoconstrictor Agents Phase 2, Phase 3,Phase 1
37 Dopamine Uptake Inhibitors Phase 2, Phase 3,Phase 1
38 Buprenorphine, Naloxone Drug Combination Phase 2, Phase 3,Phase 3,Not Applicable
39 Dopamine Agents Phase 2, Phase 3,Phase 1
40 Charcoal Phase 3
41
Oxycodone Approved, Illicit, Investigational Phase 1, Phase 2,Phase 2,Not Applicable 76-42-6 5284603
42
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
43
Pioglitazone Approved, Investigational Phase 2 111025-46-8 4829
44
Carbon monoxide Approved, Investigational Phase 2 630-08-0 281
45
Tramadol Approved, Investigational Phase 1, Phase 2 27203-92-5 33741
46
Hydromorphone Approved, Illicit Phase 1, Phase 2,Phase 2 466-99-9 5284570
47
Methylphenidate Approved, Investigational Phase 1, Phase 2 113-45-1 4158
48
Oxymorphone Approved, Investigational, Vet_approved Phase 2 76-41-5 5284604
49
Ibuprofen Approved Phase 2 15687-27-1 3672
50
Doxazosin Approved Phase 2 74191-85-8 3157

Interventional clinical trials:

(show top 50) (show all 84)
# Name Status NCT ID Phase Drugs
1 Multimodal Pain Management for Cesarean Delivery Completed NCT02922985 Phase 4 Intravenous acetominophen;Ketorolac, intramuscular;Bupivacaine, subcutaneous;Normal saline
2 Pain Control Following Sinus Surgery Not yet recruiting NCT03783702 Phase 4 OxyCODONE 5 Mg Oral Tablet;Ibuprofen 600 Mg Oral Tablet;Acetaminophen 650 MG Oral Tablet
3 Conversion to Embeda With Rescue Trial Terminated NCT01179191 Phase 4 morphine sulfate and naltrexone hydrochloride (EMBEDA)
4 Combined Therapy of Methadone and Dextromethrophan Unknown status NCT01189097 Phase 3 Dextromethorphan;Dextromethorphan
5 Cocaine Use Reduction With Buprenorphine Completed NCT01402492 Phase 2, Phase 3 Buprenorphine + Naltrexone;Placebo + Naltrexone
6 Buprenorphine Group Medical Visits in Primary Care Recruiting NCT02526212 Phase 3 Buprenorphine
7 Healthy Adult Male Facial Skin Surface Lipid Pheromone p.o. to Treat Opioid Addiction Not yet recruiting NCT03394911 Phase 3
8 Cell Phone Technology Targeting ART Adherence and Drug Use Unknown status NCT01884233 Phase 2
9 NT-814: Evaluation of Its Ability to Alter the Abuse Liability of Oxycodone in an Exploratory Clinical Study Unknown status NCT02692157 Phase 1, Phase 2 Placebo;NT-814 50 mg;NT-814 100 mg;NT-814 200 mg
10 Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse Completed NCT01967641 Phase 2 buprenorphine/naloxone combination
11 Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse Completed NCT00699010 Phase 2 Acurox 5/30mg taken first;Oxycodone 5mg taken first
12 Effective Treatment for Prescription Opioid Abuse Completed NCT00719095 Phase 2 buprenorphine taper followed by naltrexone maintenance
13 Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug Abuse Completed NCT00734461 Phase 2 oxycodone and naltrexone
14 Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone Completed NCT01395784 Phase 2 pioglitazone
15 Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users Completed NCT01030406 Phase 2 40/0mg taken first;80/0mg taken first;40/240mg taken first;80/480mg taken first;0/0mg taken first
16 Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers Completed NCT01740414 Phase 2 MN-166 (50 mg) First;Placebo First
17 A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals Completed NCT01136356 Phase 1, Phase 2 buprenorphine;morphine
18 Prescription Opioid Effects in Abusers Versus Non-Abusers Completed NCT00158184 Phase 2 oxycodone 15 mg;oxycodone 30 mg;Placebo 0 mg
19 Medication Adherence Therapy for Opioid Abusing Pain Patients Completed NCT00249587 Phase 1, Phase 2 Methadone
20 Incentive-based Smoking Cessation for Methadone Patients Completed NCT00718835 Phase 2
21 The Discriminative Effects of Tramadol in Humans Completed NCT00499746 Phase 1, Phase 2 tramadol;placebo;Hydromorphone;Methylphenidate
22 Buprenorphine as a Treatment for Individuals Dependent on Analgesic Opioids Completed NCT00218101 Phase 2 Buprenorphine
23 Buprenorphine's Dose Response Curve Completed NCT00460239 Phase 2 Buprenorphine;Morphine;Placebo
24 A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists. Recruiting NCT03389750 Phase 2 Intravenous Challege Drug
25 Ambulatory Gynecologic Surgery: Finding the Optimal Opioid Prescription Recruiting NCT03588910 Phase 2 Acetaminophen;Ibuprofen 600 mg;Oxycodone
26 Interim Buprenorphine Treatment to Bridge Waitlist Delays: Stage II Evaluation Recruiting NCT03420313 Phase 2 Buprenorphine/naloxone sublingual tablets
27 Evaluation of Doxazosin to Alter the Abuse of Oxycodone Recruiting NCT03415581 Phase 2 Intranasal Oxycodone
28 Nasal Human Abuse Potential of PTI-821 Completed NCT03475862 Phase 1 PTI-821 capsule Manipulated;PTI-821 Non-manipulated;OxyContin;Oxycodone
29 Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users Completed NCT01380093 Phase 1 Placebo;MS Contin (morphine sulfate, controlled release);EMBEDA (morphine sulfate / naltrexone hydrochloride)
30 Mindfulness-Oriented Recovery Enhancement for Chronic Pain Patients Receiving Opioid Therapy Completed NCT01505101 Phase 1
31 Effects of Posaconazole and Voriconazole on the Pharmacokinetics and Pharmacodynamics of Sublingual Buprenorphine Completed NCT01367808 Phase 1 Placebo;vorikonazole;posakonazole
32 Effects of Voriconazole on the Pharmacokinetics and Pharmacodynamics of Oral Buprenorphine: A Two-phase Cross-over Study in Healthy Subjects Completed NCT01466803 Phase 1 Placebo;Vorikonazole
33 Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo Completed NCT01595867 Phase 1 Placebo;EMBEDA - morphine sulfate/ naltrexone hydrochloride;morphine sulfate CR crushed.
34 Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder Recruiting NCT03143855 Phase 1 Lorcaserin;Placebo
35 Pain, Opioids and Pro-Inflammatory Immune Responses Terminated NCT01210066 Phase 1 Fentanyl
36 Study of Opioid Immunosuppressive Effects Unknown status NCT01881802
37 Surveillance Monitoring of Opioid Abuse in Poison and Drug Treatment Centers Unknown status NCT02871232
38 ER/LA Opioid Analgesics - Surveillance Monitoring of State Medical Examiner Databases Unknown status NCT02897414
39 Methadone Maintenance Treatment Outcome Study in Taiwan Unknown status NCT01093248
40 Mobile Health Cognitive Stimulation in Heroin Users Unknown status NCT02308878 Not Applicable
41 Computer-based Prescription Opioid Abuse Prevention for Adolescents Completed NCT02737696 Not Applicable
42 The CORE Buprenorphine Project - An HIV Primary Care Program Demonstration Completed NCT00227357 On-site - buprenorphine/naloxone (Suboxone);Off-site - methadone or no agonist
43 Opioid Prescribing After Cesarean Delivery Completed NCT03168425 Not Applicable
44 Pilot Trial of Opioid Taper Support Completed NCT01883882 Not Applicable
45 To Test a Payer/Treatment Agency Intervention to Increase Use of Buprenorphine Completed NCT01702142
46 Blockade Efficacy of Buprenorphine/Naloxone For Opioid Dependence Completed NCT00134888 Not Applicable Buprenorphine/naloxone
47 Aprepitant Effects on Oxycodone Response Completed NCT00999544 Not Applicable Aprepitant 0mg;Aprepitant 40mg;Aprepitant 200mg;Oxycodone 0mg, p.o.;Oxycodone 20mg, p.o.;Oxycodone 40mg, p.o.;Oxycodone 0mg, IN;Oxycodone 15mg, IN;Oxycodone 30mg, IN
48 Pharmacogenomics Study of Sleep Disturbance and Neurocognitive Impairments in the Opioid Addicts Completed NCT01668706
49 Taste Acuity and Caloric Intake After Acute Morphine Administration Completed NCT01763697 Not Applicable
50 Pain Management Using Mobile Technology in Veterans With PTSD and TBI Completed NCT02237885 Not Applicable

Search NIH Clinical Center for Opioid Abuse

Cochrane evidence based reviews: opioid-related disorders

Genetic Tests for Opioid Abuse

Anatomical Context for Opioid Abuse

MalaCards organs/tissues related to Opioid Abuse:

41
Testes, Brain, Heart, B Cells, Bone, Eye

Publications for Opioid Abuse

Articles related to Opioid Abuse:

(show top 50) (show all 280)
# Title Authors Year
1
Association and Effect of Opioid Abuse-Related Readmission. ( 30550433 )
2019
2
Long-term opioid users with chronic noncancer pain: Assessment of opioid abuse risk and relationship with healthcare resource use. ( 29733099 )
2018
3
Causal Analysis in Evaluating Complex Health Interventions: Identifying the Optimal Treatment for Opioid Abuse in Pregnancy. ( 29572908 )
2018
4
The prescription opioid abuse crisis and our role in it. ( 29964241 )
2018
5
The Public and the Opioid-Abuse Epidemic. ( 29298128 )
2018
6
Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose. ( 29615715 )
2018
7
The role of managed care professionals and pharmacists in combating opioid abuse. ( 29851451 )
2018
8
Opioid Abuse or Dependence Increases 30-day Readmission Rates after Major Operating Room Procedures: A National Readmissions Database Study. ( 29470180 )
2018
9
Tramadol (opioid) abuse is associated with a dose- and time-dependent poor sperm quality and hyperprolactinaemia in young men. ( 29781510 )
2018
10
The FDA's Latest Response to Opioid Abuse and Overdose. ( 29280800 )
2018
11
Opioid Abuse and Death: Thoughts From Dayton, Ohio. ( 29933441 )
2018
12
Intranasal tissue necrosis associated with opioid abuse: Case report and systematic review. ( 29280484 )
2018
13
Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting. ( 29989247 )
2018
14
Risks of opioid abuse among uninsured primary care patients utilizing a free clinic. ( 30040586 )
2018
15
Letter to the Editor: A Case for Opioid Education and Training for Medical Students, Residents, and Allied Health Staff: Response to "Educational Intervention for Physicians to address the risk of Opioid Abuse". ( 30044479 )
2018
16
Ethical dimensions of the prescription opioid abuse crisis. ( 30045851 )
2018
17
Management Strategies in Opioid Abuse and Sexual Dysfunction: A Review of Opioid-Induced Androgen Deficiency. ( 30057139 )
2018
18
Opioid abuse/dependence among those hospitalized due to periapical abscess. ( 30066389 )
2018
19
Prevalence of Emergency Department Patients Presenting with Heroin or Prescription Opioid Abuse Residing in Urban, Suburban, and Rural Jefferson County. ( 30253947 )
2018
20
Risk of behaviour suggestive of opioid abuse: a protocol for a systematic review of validated assessment tools. ( 30282680 )
2018
21
Determinants of opioid abuse potential: Insights using intracranial self-stimulation. ( 30391425 )
2018
22
Opioid Abuse and Dependence in Those Hospitalized Due to Head and Neck Cancer. ( 30509393 )
2018
23
Promoting opioid overdose prevention and recovery: An exploratory study of an innovative intervention model to address opioid abuse. ( 30551002 )
2018
24
Chronic pain and opioid abuse: Factors associated with health-related quality of life. ( 29160596 )
2017
25
Interprofessional prescription opioid abuse communication among prescribers and pharmacists: A qualitative analysis. ( 28799863 )
2017
26
Toolkit aims to make adolescents aware of dangers of opioid abuse. ( 28483935 )
2017
27
The Economic Burden of Opioid Abuse: Updated Findings. ( 28345440 )
2017
28
Screening tools to assess risk of opioid abuse in the Canadian primary healthcare setting. ( 28346282 )
2017
29
Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse (Part 2). ( 28226334 )
2017
30
Review of Factors, Methods, and Outcome Definition in Designing Opioid Abuse Predictive Models. ( 29016966 )
2017
31
The Use of Continuous Ketamine for Analgesia and Sedation in Critically Ill Patients with Opioid Abuse: A Case Series. ( 29967888 )
2017
32
Collaboration Needed: Pain Care and Opioid Abuse. ( 27681886 )
2017
33
Prescription opioid abuse in prison settings: A systematic review of prevalence, practice and treatment responses. ( 28086177 )
2017
34
Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration. ( 28414990 )
2017
35
"I am in pain": is it really the magic formula to open the door of opioid abuse? ( 28726366 )
2017
36
Opioid Abuse And Poisoning: Trends In Inpatient And Emergency Department Discharges. ( 28971919 )
2017
37
Epidemiology of Opioid Abuse and Addiction. ( 28372767 )
2017
38
The ALERRT(Ar) instrument: a quantitative measure of the effort required to compromise prescription opioid abuse-deterrent tablets. ( 28448223 )
2017
39
Treating postoperative pain in the patient who is in recovery or remission from opioid abuse: Focus on Tapentadol. ( 29441514 )
2017
40
Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse: Part 1. ( 28226333 )
2017
41
You never know when you'll need a Vicodin: An era of opioid abuse. ( 28400252 )
2017
42
Drivers of excess costs of opioid abuse among a commercially insured population. ( 28738684 )
2017
43
Corrigendum: The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting. ( 28318019 )
2017
44
Macroeconomic conditions and opioid abuse. ( 29128677 )
2017
45
The Opioid Abuse Risk Screener predicts aberrant same-day urine drug tests and 1-year controlled substance database checks: A brief report. ( 29379630 )
2017
46
Identification of Opioid Abuse or Dependence: No Tool Is Perfect. ( 28215952 )
2017
47
An overview of available drugs for management of opioid abuse during pregnancy. ( 28203387 )
2017
48
Opioid Abuse: A Detailed Examination of Cost Drivers over a 24-Month Follow-up Period. ( 29083966 )
2017
49
Educational intervention for physicians to address the risk of opioid abuse. ( 29199396 )
2017
50
Marshaling FDA Benefit-Risk Expertise to Address the Current Opioid Abuse Epidemic. ( 28687816 )
2017

Variations for Opioid Abuse

Expression for Opioid Abuse

Search GEO for disease gene expression data for Opioid Abuse.

Pathways for Opioid Abuse

GO Terms for Opioid Abuse

Cellular components related to Opioid Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.54 CCK DRD2 OPRM1
2 integral component of presynaptic membrane GO:0099056 9.32 DRD2 OPRM1
3 axon terminus GO:0043679 9.26 DRD2 PDYN
4 dendrite GO:0030425 9.26 CCK DRD2 OPRM1 PDYN
5 integral component of postsynaptic membrane GO:0099055 9.16 DRD2 OPRM1
6 perikaryon GO:0043204 8.8 CCK DRD2 OPRM1

Biological processes related to Opioid Abuse according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 neuropeptide signaling pathway GO:0007218 9.67 OPRL1 OPRM1 PDYN
2 excitatory postsynaptic potential GO:0060079 9.63 DRD2 OPRM1
3 axonogenesis GO:0007409 9.63 CCK CCKAR DRD2
4 G protein-coupled receptor signaling pathway GO:0007186 9.63 CCK CCKAR DRD2 OPRL1 OPRM1 PDYN
5 forebrain development GO:0030900 9.62 CCKAR DRD2
6 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.62 OPRL1 OPRM1
7 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.61 CCKAR OPRM1
8 sensory perception of pain GO:0019233 9.61 OPRL1 OPRM1
9 visual learning GO:0008542 9.6 CCK DRD2
10 response to cocaine GO:0042220 9.59 DRD2 OPRM1
11 feeding behavior GO:0007631 9.58 CCKAR DRD2
12 response to morphine GO:0043278 9.58 DRD2 OPRM1
13 negative regulation of blood pressure GO:0045776 9.57 DRD2 OPRL1
14 positive regulation of neurogenesis GO:0050769 9.56 DRD2 OPRM1
15 response to light stimulus GO:0009416 9.55 DRD2 MAPK10
16 estrous cycle GO:0044849 9.52 OPRL1 OPRM1
17 positive regulation of urine volume GO:0035810 9.51 DRD2 OPRL1
18 sensory perception GO:0007600 9.48 OPRL1 OPRM1
19 behavioral response to ethanol GO:0048149 9.43 DRD2 OPRM1
20 negative regulation of voltage-gated calcium channel activity GO:1901386 9.4 DRD2 OPRL1
21 opioid receptor signaling pathway GO:0038003 9.37 OPRL1 OPRM1
22 positive regulation of sensory perception of pain GO:1904058 9.32 CCK OPRL1
23 negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0106072 9.26 OPRL1 OPRM1
24 regulation of sensory perception of pain GO:0051930 9.13 CCK OPRL1 OPRM1
25 eating behavior GO:0042755 8.8 CCK OPRL1 OPRM1
26 signal transduction GO:0007165 10.01 CCK CCKAR DRD2 MAPK10 OPRL1 OPRM1

Molecular functions related to Opioid Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.46 CCKAR DRD2 OPRL1 OPRM1
2 neuropeptide binding GO:0042923 8.96 OPRL1 OPRM1
3 opioid receptor activity GO:0004985 8.62 OPRL1 OPRM1

Sources for Opioid Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....